Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 19861 AL 19875

Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease

da Cruz e Silva OA, Henriques AG, Domingues SC, da Cruz e Silva EF.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):720-6. doi: 10.2174/187152710793237458.

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative

Oksengard AR, Cavallin L, Axelsson R, Andersson C, Nägga K, Winblad B, Eriksdotter-Jönhagen M, Wahlund LO.

Dement Geriatr Cogn Disord. 2010;30(4):374-80. doi: 10.1159/000321121. Epub 2010 Oct 16.

N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers

Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST.

J Neurochem. 2010 Dec;115(6):1520-9. doi: 10.1111/j.1471-4159.2010.07058.x. Epub 2010 Nov 11.

Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease

Camandola S, Mattson MP.

Biochim Biophys Acta. 2011 May;1813(5):965-73. doi: 10.1016/j.bbamcr.2010.10.005. Epub 2010 Oct 13.

MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains

Satoh J.

J Pharmacol Sci. 2010;114(3):269-75. doi: 10.1254/jphs.10r11fm. Epub 2010 Oct 9.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

The genetics of Alzheimer disease: back to the future

Bertram L, Lill CM, Tanzi RE.

Neuron. 2010 Oct 21;68(2):270-81. doi: 10.1016/j.neuron.2010.10.013.

Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider

Biondi E.

Neurol Sci. 2011 Apr;32(2):195-201. doi: 10.1007/s10072-010-0440-0. Epub 2010 Oct 19.

Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

Guo S, Hernandez L, Wasiak R, Gaudig M.

J Med Econ. 2010;13(4):641-54. doi: 10.3111/13696998.2010.528101. Epub 2010 Oct 19.

[An autopsy case of senile dementia suspected to be influenced by cerebral amyloid angiopathy with multiple cortical microinfarcts]

Iwasaki Y, Mori K, Ito M, Deguchi A, Shiraishi T, Mimuro M, Yoshida M, Hashizume Y.

Rinsho Shinkeigaku. 2010 Sep;50(9):651-5. doi: 10.5692/clinicalneurol.50.651.

When neurogenesis encounters aging and disease

Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, van Praag H.

Trends Neurosci. 2010 Dec;33(12):569-79. doi: 10.1016/j.tins.2010.09.003. Epub 2010 Oct 18.

Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases

Anoop S, Misra A, Meena K, Luthra K.

Indian J Med Res. 2010 Oct;132:363-78.

Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress

Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A.

Mol Psychiatry. 2010 Nov;15(11):1046-52. doi: 10.1038/mp.2010.17.

[Alteration of calcium signaling as one of the mechanisms of Alzheimer's disease and diabetic polyneuropathy]

Kostiuk OP, Korol' TIu, Korol' SV, Romanenko SV, Pinchenko VO, Kostiuk PH.

Fiziol Zh (1994). 2010;56(4):130-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias